Explanation:
ND-630 decreases fatty acid synthesis. It stimulates fatty acid oxidation in cultured cells. Further, it reduces hepatic steatosis, enhances insulin sensitivity, reduces weight gain without having an impact on food intake.
ND-630 is an allosteric inhibitor of acetyl-CoA carboxylase (ACC) dimerization. It that inhibits ACC1 and ACC2 activity (IC50s = 2.1 and 6.1 nM, respectively, for the human enzymes). It is selective for ACC over 101 enzymes, receptors, growth factors, transporters, and ion channels up to a concentration of 10 µM. ND-630 prevents dimerization of ACC by interacting within the phosphopeptide-acceptor and dimerization site.
HD-630 affects dyslipidemia and reduces hepatic steatosis, improves glucose-stimulated insulin secretion. It reduces haemoglobin A1c in Zucker diabetic fatty rats. ND- 630 modulates key metabolic parameters in liver and muscle. Also, it modulates key plasma and liver lipids in-vivo (decreases liver free fatty acids, decrease plasma triglycerides, decrease plasma cholesterol).
ND- 630 may be beneficial in the treatment of metabolic disorders (metabolic syndrome, diabetes II, fatty liver disorder). ND-630 is effective in disorders such as liver disease progression from nonalcoholic fatty to non-alcoholic steatohepatitis and hepatocellular carcinoma.
ND-630 is hepatoselective inhibitor of Acetyl-CoA carboxylase to affect these liver disorders. It is a selective allosteric inhibitor and is modulating NASH-relevant endpoints.
It has an ability for tissue targeted ACC inhibition to improve metabolic syndrome pathways, decrease liver steatosis, decrease expression of inflammatory markers and improve fibrosis.
ND-630 can reduce acutely malonyl-CoA in the liver (reducing hepatic FASyn) and in certain muscles of rats; the soleus (containing primarily type slow-twitch oxidative fibres), the extensor digitorum longus (containing primarily type II fast-twitch glycolytic fibres), the gastrocnemius (containing both fibres).
In recent research, no ND-630–related clinical signs and no changes in body weight, food consumption, haematology, coagulation, or clinical chemistries were observed. There were no toxicologically significant findings in clinical chemistry associated with liver, kidney, or muscle integrity or function.
Certain allosteric proteins such as acetyl-CoA carboxylase inhibitors may inhibit enzymatic activity.
